RSS

Advanced Search

Printed From BioPortfolio.com

+ News Categories + Corporate Categories + Report Categories

Article

Latest Articles on life science, biotechnology, pharmaceutical and healthcare topics and current issues.

Search Articles

Showing News Articles 1–25 of 13103

Last Hour Last 24 Hours May 2012 Apr 2012 Mar 2012 Feb 2012 Jan 2012 Dec 2011 Advanced Search

Order

Date Published

Source

Keyword

* Minimum 4 characters

or Cancel

Sat 26 May 2012

[Articles] Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomiseREGN727 was well tolerated and achieved substantial further LDL-C reduction in patients with heterozygous familial hypercholesterolaemia and elevated LDL-C treated with high-dose statins, with or without ezetimibe. REGN727 has the potential to provid...

[Comment] Inhibition of PCSK9 in familial hypercholesterolaemiaStatins are indicated for treatment of patients with heterozygous familial hypercholesterolaemia: these drugs inhibit hepatic cholesterol synthesis and indirectly raise transcription and expression of low-density lipoprotein (LDL) receptors, resultin...

Fri 25 May 2012

[Articles] Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trialIntravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended.

[Comment] Magnesium and neuroprotection in subarachnoid haemorrhageNeuroprotection in aneurysmal subarachnoid haemorrhage has been extensively investigated because of the disease's high morbidity and mortality in young adults. Neurological factors that affect clinical outcome include increased intracranial pressure...

MPM Capital; How to spot a winner- Good data trumps everythingIn this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to Vaughn Kailian, Managing Director of MPM Capital

BioLineRx: 'Bench to Bedside to Partner' - Bridging the gap between academia and pharmaIn this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to David Malek, Vice Preident of Business Development of BioLineRx.

Full access to trial data holds many benefits and a few pitfalls, conference hearsAn era of open, transparent, and accessible data from pharmaceutical research holds huge promise and some dangers, a conference organised by the BMJ Group and the Association of the British...

The drug industry is a barrier to diabetes care in poor countriesIn many parts of the world, people with type 1 diabetes (whether or not the condition is diagnosed) still die for want of insulin, and those with type 2 diabetes go without treatments that prolong...

Health department is to shut down patient records site that was too hard to useThe Department of Health in England is to close a patient records website that was judged “too difficult” to use by one of the government’s leading health technology experts.Charles Gutteridge, the...

Doctors opposed to NHS reforms set up a new political partyA group of doctors and public health experts, disillusioned by the government’s changes to the NHS, are setting up a new political party because they don’t think that any of the existing parties...

Catholics sue Obama over provision of contraception in health insurance policiesLeading Roman Catholic organisations have sued the Obama administration over the requirement that health insurance policies must cover contraception for their workers from 1 August. They claim that...

England and Wales finally get first chief coronerPeter Thornton, the Old Bailey judge who presided over the inquest into the death of the newspaper seller Ian Tomlinson during the G20 protests in 2009,1 will become the first chief coroner for...

Human medicines European Public Assessment Report (EPAR): Renagel, sevelamer, Revision: 19, Authorised

Human medicines European Public Assessment Report (EPAR): Pergoveris, follitropin alfa / lutropin alfa, Revision: 6, Authorised

Human medicines European Public Assessment Report (EPAR): Liprolog, insulin lispro, Revision: 14, Authorised

Veterinary medicine European Public Assessment Report (EPAR): Convenia, Cefovecin, Revision: 6, Authorised

Good News: Fukushima Radiation Should Not Cause a Rise in Cancer Cases | 80beats

Two new reports on radiation doses received by workers and civilians near the Fukushima Daiichi nuclear meltdown last year indicate that there will be very little, if any, increase in their cancer risk. The reports, put together by the United Nation...

Investigation of acute knee injuryLearning pointsPlain radiographs often show no fractures after acute knee injuries; even serious internal derangements of the knee may be occult on radiographsThe Ottawa rule is recommended for...

The Medicalization of Everyday Life“Psychiatry is medicalization, through and through. Whatever aspect of psychiatry psychiatrists claim is not medicalization, is not medicalization only if it deals with proven disease, in which case...

Playing the oddsTwice now in about as many months she’s led me, only half attending, into this trap.First she tells me of a raffle ticket she bought for a chance to win a car. “Yes, you told me that,” I say, “I hope...

Book Review: Sperm Counts - Overcome by Man's Most Precious FluidThe fluidity of semen is an idea that Lisa Jean Moore returns to throughout her book 'Sperm Counts: Overcome by Man's Most Precious Fluid', though she is often less concerned with the physical qualities of the substance than she is with its fluidity...

News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 May 2012This page lists the opinions adopted at the May 2012 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.

News and press releases: European Medicines Agency recommends first-in-class medicine for treatment of cystic fibrosisThe European Medicines Agency has recommended Kalydeco (ivacaftor), an orphan-designated medicine, for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the cystic fibrosis transmembrane regulator (CFTR)...

News and press releases: European Medicines Agency confirms positive benefit-risk balance of MabTheraFollowing a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the batches of the active substance of MabThera, rituxim...

News and press releases: European Medicines Agency updates patient and prescriber information for PradaxaThe European Medicines Agency has recommended updating the product information for the blood thinner Pradaxa, to give clearer guidance to doctors and patients on how to reduce and manage the risk of bleeding associated with the anticoagulant medicine...

0 1 2 3 4 ›»